Baxdrostat
CinCor Pharma
[]
cincor $cinc pharma announces late-breaking presentation of phase 2 brightn data on baxdrostat in treatment-resistant hypertension at the 2022 american heart association scientific sessions 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)